Braaten and colleagues from Johns Hopkins School of Medicine have reported their experience with chronic inflammatory arthritis induced by immune checkpoint inhibitor therapies (ICI) showing that in some, inflammatory arthritis persists after the immunotherapy has been discontinued.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Dr. Jack Cush reports the news and important journal articles from the past week on RheumNow.com.
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, including new SLE criteria, ULT in gout and MSU reductions, IVIG in ANCA vasculitis and non-TNF biologics outperform the TNF inhibitors.
Dr. Jack Cush reviews the news, journal reports, and FDA releases and deliberations covered this past week on RheumNow.com
Dr. Jack Cush reviews this week's news and journal reports featured on RheumNow.com.
At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed. Agreement for principles with respect to the treatment of immune mediated adverse events from cancer immunotherapy are lacking.
A better understanding of rheumatic immune-related adverse event phenotypes beyond inflammatory arthritis has been furthered by work from three abstracts presented at EULAR 2019 in Madrid.
EULAR 2019 begins today in Madrid and features over 2000 presentations. After an initial review of titles and abstracts, I’ve compiled a hit list of presentations of interest to me and hopefully other practicing rheumatologists.
Reuters has reported that Mallinckrodt Plc has tentatively agreed to pay $15.4 million to resolve a US Justice Department investigation into company promotional practices for Acthar gel.
Links:
Dr. John Cush @RheumNow ( View Tweet )
Links:
Links:
Dr. John Cush @RheumNow ( View Tweet )
Links:
Links:
Links:
Links:
Links:
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
